Baxano Surgical, Inc., formerly Baxano Inc. is a medical device company. The Company is focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region. The Company markets the AxiaLIF pre-sacral access and interbody fusion system for single and two level lower lumbar fusion, the VEO lateral access and interbody fusion system, the iO-Flex set of flexible instruments used by surgeons during spinal decompression procedures, and the iO-Tome instrument for rapid and precise removal of bone, specifically the facet joints, a technique which is commonly performed in spinal fusion procedures. The Company's other products include: Vectre facet screw system, Bi-Ostetic bone void filler, bowel retractors, discectomy tools, and a bone graft harvesting system that can be used to extract bone graft from the patient's hip for use in fusion procedures.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:BAXS
- CUSIP: N/A
- Web: baxanosurgical.com
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.06
- P/E Growth: N/A
- Net Margins: -126.01%
- Return on Equity: -117.23%
- Return on Assets: -56.63%
Frequently Asked Questions for Baxano Surgical (NASDAQ:BAXS)
What is Baxano Surgical's stock symbol?
Baxano Surgical trades on the NASDAQ under the ticker symbol "BAXS."
How were Baxano Surgical's earnings last quarter?
Baxano Surgical Inc (NASDAQ:BAXS) released its quarterly earnings data on Tuesday, August, 5th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.04. Baxano Surgical had a negative net margin of 126.01% and a negative return on equity of 117.23%. View Baxano Surgical's Earnings History.
Who are some of Baxano Surgical's key competitors?
Some companies that are related to Baxano Surgical include Orange Belgium (MBSRF), Apple (AAPL), Alphabet (GOOGL), Alphabet (GOOG), Microsoft Corporation (MSFT), Facebook (FB), Amazon.com (AMZN), Berkshire Hathaway (BRK-A), Premier Foods Spon (PRRFY), Industrial & Cmrcl Bnk f China Ltd (IDCBY), Nestle SA (NSRGY), RDS-A (RDS-A), Roche Holding (RHHBY), China Const Bk (CICHY), Comcast Corporation (CMCSA), Intel Corporation (INTC), DowDuPont (DWDP) and Cisco Systems (CSCO).
How do I buy Baxano Surgical stock?
Shares of Baxano Surgical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Baxano Surgical's stock price today?
MarketBeat Community Rating for Baxano Surgical (NASDAQ BAXS)MarketBeat's community ratings are surveys of what our community members think about Baxano Surgical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Baxano Surgical stock can currently be purchased for approximately $0.02.
Consensus Ratings for Baxano Surgical (NASDAQ:BAXS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Baxano Surgical (NASDAQ:BAXS)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Baxano Surgical (NASDAQ:BAXS)Earnings History by Quarter for Baxano Surgical (NASDAQ BAXS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/8/2013||Q2 2013||($0.14)||($0.21)||$6.90 million||$3.90 million||View||N/A|
Earnings Estimates for Baxano Surgical (NASDAQ:BAXS)
Current Year EPS Consensus Estimate: $-0.5700 EPS
Next Year EPS Consensus Estimate: $-0.4000 EPS
Dividend History for Baxano Surgical (NASDAQ:BAXS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Baxano Surgical (NASDAQ:BAXS)Insider Trades by Quarter for Baxano Surgical (NASDAQ:BAXS)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/15/2014||Kenneth Michael Reali||CEO||Buy||10,000||$0.38||$3,800.00|| |
|5/12/2014||Kenneth Michael Reali||CEO||Buy||7,050||$0.71||$5,005.50|| |
|12/5/2013||Kenneth Michael Reali||CEO||Buy||10,500||$1.11||$11,655.00|| |
|5/31/2013||Roderick A Young||Director||Buy||1,340,034||$2.28||$3,055,277.52|| |
Headline Trends for Baxano Surgical (NASDAQ:BAXS)
Latest Headlines for Baxano Surgical (NASDAQ:BAXS)
Baxano Surgical (BAXS) Chart for Thursday, September, 21, 2017